Objectives-Factors contributing to the development of systemic lupus erythematosus (SLE) remain largely unknown although are likely to include both environmental and genetic components. Studies on murine lupus have indicated a role for an antibody that blocks binding of cytotoxic T lymphocyte associated-4 (CTLA-4) to B7 on antigen presenting cells in the treatment of disease, suggesting that CTLA-4 may play an important part in the disease process. This study, therefore, investigated the frequency of a previously described A-G polymorphism in exon 1 of the CTLA-4 gene, the G allele of which has shown to be associated with both Graves' disease and type I diabetes, to determine whether this polymorphism was playing a part in the development of SLE. Methods-One hundred and twenty six SLE patients and 363 control subjects were genotyped for the A-G polymorphism in exon 1 of the CTLA-4 gene. Target DNA was amplified using the polymerase chain reaction and the resulting product was digested using the BbvI restriction enzyme. Results-No diVerences in allele or genotype frequencies were observed between patients with SLE and control subjects. Conclusion-These data suggest that the A-G polymorphism in exon 1 of the CTLA-4 gene does not play a part in the genetic susceptibility to the development of SLE. (Ann Rheum Dis 1999;58:193-195) 
Systemic lupus erythematosus (SLE) is a multisystem disorder characterised by the presence of many antibodies. The aetiology of the disease is unknown but is thought to be caused by both genetic and environmental factors. SLE can occur at any age, and although 10-12% of patients have first degree relatives with the disease, 1 the aVected family members may present at similar time points suggesting the involvement of external environmental stimuli. 2 Despite this, the involvement of genetic components is still highly probable with concordance rates in monozygotic twins of between 24 and 69% compared with 2-9% in dizygotic twins. 3 Genetic studies in SLE have suggested roles for the MHC class II region (HLA) on chromosome 6p, 4 the heat shock protein genes, 5 and the tumour necrosis factor gene. 6 However, the latter two may only be associated with disease on certain HLA haplotypes and the HLA region itself seems to be highly associated with the production of autoantibodies rather than with the disease itself, leaving the primary genetic components of SLE to be determined. Studies of SLE in both humans and mice have shown that the production of autoantibodies by B cells is dependent upon stimulation from CD4+ T cells. 7 8 Consequently any molecules that play a part in the interaction of B and T cells could be involved in the disease process. Cytotoxic T lymphocyte associated-4 (CTLA-4) is involved in the regulation of T cells and is a member of the same family of cell surface molecules as CD28. Both of these molecules bind to B7 on B cells and the CTLA4-B7 complex can compete with the CD28/B7 complex and deliver negative signals to the T cell aVecting T cell proliferation, cytokine production, and immune responses. 9 After the observation that selective inhibition of B7-CTLA-4 interaction can produce antispecific T cell unresponsiveness in vitro and suppress immune function in vivo, experiments were performed to determine whether selective inhibition of B7-CTLA-4 interaction could suppress spontaneous autoimmune disease. Lupus prone NZB/NZW F1 mice were treated with a murine CTLA-4 immunoglobulin (muCTLA-4Ig), which blocked autoantibody production and prolonged life even when treatment was delayed until after the onset of clinical disease. 10 The CTLA-4 gene is located on chromosome 2q33 and was initially investigated as a candidate for autoimmune thyroid disease. Subsequently an AT repeat microsatellite in the 3' untranslated region of exon 3 and a threonine to alanine (A-G) polymorphism at position 49 in exon 1, have been reported to be associated with both Graves' disease and type I diabetes. 11 The aim, therefore, of this study was to investigate the frequency of the A-G polymorphism of the CTLA-4 gene in a population based case-control study to determine whether the CTLA-4 gene plays a part in genetic susceptibility to SLE.
Methods

PATIENTS
One hundred and twenty six white patients were recruited from the SLE clinic in the Rheumatology Department of the Queen Elizabeth Hospital and University of Birmingham, Birmingham. The patients fulfilled the American College of Rheumatology criteria for the classification of SLE. 12 Blood was obtained from 363 ethnically matched control subjects with no history of autoimmune disease at various sites including the Blood Transfusion Service, Birmingham Heartlands Hospital and the Queen Elizabeth Hospital, Birmingham.
The study was approved by the local ethics committee and all subjects gave informed, written consent.
GENOTYPING AND STATISTICAL ANALYSIS
Genomic DNA was extracted from 10 ml of blood using the Bacc II DNA extraction kit from Nucleon Biosciences. Amplification of the target DNA in exon 1 of the CTLA-4 gene was carried out by the polymerase chain reaction (PCR) using primers:-5' GTC AAG GGA CCA TTA GAA G 3' and 5' CTT TGC AGA AGA CAG GGA TGA A 3' under appropriate reaction conditions. The resulting product was then subjected to restriction fragment length polymorphism (RFLP) analysis with the enzyme BbvI and the digestion products were termed A and G. To verify that complete digestion had occurred, selected samples were subjected to sequencing analysis using the ABI Prism 377 from Applied Biosystems.
Statistical analysis of results was performed using the 2 test. A p value of less than 0.05 was considered to be significant.
Results
Samples from 126 SLE patients and 363 control subjects were successfully genotyped for the A-G polymorphism in exon 1 of the CTLA-4 gene. Table 1 summarises the results obtained from the study. Similar allele and genotype frequencies were observed in both the SLE patients and control subjects. Sequencing data verified alleles found by RFLP analysis.
Discussion
The A-G polymorphism at position 49 in exon 1 of the CTLA-4 gene encodes a threonine to alanine substitution in the leader peptide. The G allele (encoding alanine) has been shown to be associated with both Graves' disease and type I diabetes.
11
A recent report on murine lupus suggests that treatment of the disease with a muCTLA4Ig blocks autoantibody production and prolongs life even in animals in advanced stages of clinical illness. 10 This suggests that CTLA-4 is playing a part in the disease process at an immunological level-a hypothesis supported by the finding that the production of autoantibodies by B cells is dependent on stimulation from CD4+ T cells, 7 8 on which CTLA-4 is expressed. This finding has important implications for the treatment of human lupus as there is 76% homology between murine and human CTLA-4 with complete conservation in the cytoplasmic domain 13 suggesting that this domain may be important in CTLA-4 function in both species. The mechanism by which muCTLA-4Ig suppresses murine lupus is as yet unknown although several hypotheses have been suggested. It may bind to B7 on B cells and prevent binding of CD28 thus inhibiting T cell activation 10 or it may block the interaction of CTLA-4 and B7.
14 Alternatively, instead of exerting an eVect on T cell function, it may act directly on B cells and inhibit autoantibody production by depleting activated B cells. There is however no evidence to support this hypothesis. 10 Although the A-G polymorphism of the CTLA-4 gene is associated with Graves' disease and type I diabetes, we found no association with SLE. This finding is in correlation with a recent study 15 that found no association of the (AT)n microsatellite, found in exon 3 of the CTLA-4 gene and in linkage disequilibrium with the A-G polymorphism, with SLE. Lack of association of the A-G polymorphism with SLE may be explained by the polymorphism not being in linkage disequilibrium with a predisposing allele of a disease causing mutation in SLE-a possibility as the threonine to alanine substitution is not expected to aVect the function of the leader peptide or simply because the CTLA-4 gene polymorphism is not suYcient to influence disease expression in SLE. However, it seems more likely that the CTLA -4 gene itself is not involved in development of this disease and that the role of CTLA-4 is purely as an immunological molecule.
In conclusion, lack of association of the A-G polymorphism with SLE indicates that this region of the CTLA-4 gene is neither a disease causing mutation nor is it in linkage disequilibrium with such a mutation in SLE patients, in contrast with Graves' disease and type I diabetes. 
